Autologous Cord Blood Mononuclear Cells for Bronchopulmonary Dysplasia in Very Preterm Neonates
Status:
Completed
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
Rationale: Pre-clinical animal studies provide robust evidence regarding the beneficial
effect of cord blood-derived mononuclear cells (MNCs) for experimental bronchopulmonary
dysplasia (BPD).
This single-center, randomized, controlled, blinded trial assessed the effect of a single
intravenous infusion of autologous cord blood MNCs (ACBMNCs) in preventing BPD in very
preterm neonates, a high-risk population.
Phase:
Phase 2
Details
Lead Sponsor:
Guangdong Women and Children Hospital Guangdong Women and Children's Hospital and Health Institute